bioAffinity Technologies, Inc. (BIAFW) stock
BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value
$0.24+0.00 (0.00%)
Close on Oct 30, 2026Market cap $23.58MP/E –Yield –
bioAffinity Technologies cash
Cash and short-term investments held at the end of each period.
bioAffinity Technologies's cash was $2.43M at Jun 30, 2026. For fiscal 2025 it was $6.45M, up 483.5% from the year before. The highest annual figure on record is $11.41M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.45M | +483.5% |
| FY2024 | Dec 31, 2024 | $1.11M | -60.8% |
| FY2023 | Dec 31, 2023 | $2.82M | -75.3% |
| FY2022 | Dec 31, 2022 | $11.41M | +738.9% |
| FY2021 | Dec 31, 2021 | $1.36M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.43M | +202.6% |
| Q1 FY2026 | Mar 31, 2026 | $3.10M | +596.7% |
| Q4 FY2025 | Dec 31, 2025 | $6.45M | +483.5% |
| Q3 FY2025 | Sep 30, 2025 | $7.67M | +913.7% |
| Q2 FY2025 | Jun 30, 2025 | $802.84K | +0.2% |
| Q1 FY2025 | Mar 31, 2025 | $444.71K | -81.9% |
| Q4 FY2024 | Dec 31, 2024 | $1.11M | -60.8% |
| Q3 FY2024 | Sep 30, 2024 | $756.58K | -83.2% |
| Q2 FY2024 | Jun 30, 2024 | $801.31K | -90.3% |
| Q1 FY2024 | Mar 31, 2024 | $2.45M | -74.9% |
| Q4 FY2023 | Dec 31, 2023 | $2.82M | -75.3% |
| Q3 FY2023 | Sep 30, 2023 | $4.51M | -66.6% |
| Q2 FY2023 | Jun 30, 2023 | $8.28M | +508.5% |
| Q1 FY2023 | Mar 31, 2023 | $9.77M | – |
| Q4 FY2022 | Dec 31, 2022 | $11.41M | – |
| Q3 FY2022 | Sep 30, 2022 | $13.50M | – |
| Q4 FY2021 | Dec 31, 2021 | $1.36M | – |